Cryo-EM reveals critical OST complex and potential drug target
Posted: 24 January 2018 | Dr Zara Kassam (Drug Target Review) | No comments yet
Scientists have revealed the atomic-level structure of a molecular complex responsible for modifying proteins, paving the way for the development of new medications…


Scientists have revealed the atomic-level structure of a molecular complex responsible for modifying proteins, possibly paving the way for the development of new medications for cancer and a host of other diseases.
The complex, known as OST, is a key player in protein glycosylation, a wide-spread cell process that is intimately linked to numerous functions in the human body. It works by adding sugars called glycans to proteins, influencing their shape and, as a result, their function.
“The determination of the atomic-level structure of OST is a breakthrough in glycobiology,” said Dr Huilin Li, a Professor at Van Andel Research Institute (VARI) and senior author on a study. “As a key enzyme in the N-linked glycan biosynthesis pathway, OST is important in both health and disease. We hope these findings will lead to life-changing therapies for cancer and many other disorders.”
Drug Target Review has just announced the launch of its NEW and EXCLUSIVE report examining the evolution of AI and informatics in drug discovery and development.
In this 63 page in-depth report, experts and researchers explore the key benefits of AI and informatics processes, reveal where the challenges lie for the implementation of AI and how they see the use of these technologies streamlining workflows in the future.
Also featured are exclusive interviews with leading scientists from AstraZeneca, Auransa, PolarisQB and Chalmers University of Technology.
Most proteins modified by OST are either secreted or become embedded in the cell surface membrane, where they act as a conduit between the cell and its environment. Their exposure to the cells’ surroundings and the presence of glycans make them ideal targets for new medications, which often use glycans’ specific chemical signatures to zero in on a cancer cell, for example.
Although OST was discovered many decades ago, its structure remained unclear. The atomic structure of OST described in today’s paper is from baker’s yeast, a simple and elegant model for biomedical research.
Unlike other complexes that are assembled by interactions between proteins, the eight membrane proteins that comprise OST are largely “glued” together by seven phospholipid molecules in the centre of its structure. These lipids made the complex difficult to purify for structural analysis.
“The intricacy and novelty of OST’s structure is truly remarkable,” said Dr Lin Bai, a senior research scientist in Li’s lab and first author on the paper. “The structure is the culmination of more than a decade of work, and provides important clarity and insight into a common cellular process that affects half the proteins in the human body.”
The structure suggests functional roles for its eight component proteins, which were recruited to the catalytic core enzyme over billions of years of evolution. Some of these proteins were found to recognize the donor substrate glycan or acceptor proteins, while others coordinate with protein synthesis and protein translocation machinery–processes that are vital to maintaining life.
The structure also reveals key reaction sites that may be targeted by drugs designed to correct dysfunctions in diseases like cancer.
The research has been published in Nature.
Related topics
Drug Targets, Label-free, Microscopy
Related conditions
Cancer
Related organisations
Van Andel Research Institute (VARI)
Related people
Dr Huilin Li, Dr Lin Bai


